Fig. 8: URI combination with SCD1 is associated with poor survival and sorafenib-resistance in advanced HCC patients.

a Representative images of mIHC/IF on samples from cohort A with BCLC B/C stage HCC (n = 134 patients). URI, green; SCD1, red. Nuclei, DAPI (blue). Para-tumor, the adjacent normal-like tissue. Scale bar, 200 μm. b Pearson’s correlation between URI and SCD1 expression in HCC tissues in cohort A by two-tailed test (n = 134 patients). c Percentage of samples with high expression of URI and SCD1 in cohort A. T, tumor; P, para-tumor (n = 134 patients). d Survival analysis of four subgroups (URI low/SCD1 low, URI high/SCD1 low, URI low/SCD1 high and URI high/SCD1 high) from cohort A (n = 134 patients). e The transcriptional status of certain genes between URI^high versus URI^low patients with wild-type p53 from Fudan_HCC_Cohort⁴⁵, the transcriptional levels were showed as log2 values of gene FPKM ratios between tumor (T) and paired non-tumor (NT), and the URI^high patients had higher URI levels in tumors than their paired non-tumor tissues, while the URI^low patients had lower tumoral URI levels than non-tumor tissues. f Recurrence free survival analysis and overall survival analysis of URI^high group and URI^low group in Fudan_HCC_Cohort with wild-type p53 (n = 52 patients). g Recurrence free survival analysis and overall survival analysis of SCD1^high and SCD1^low group in Fudan_HCC_Cohort with wild-type p53 (n = 52 patients), the SCD1^high patients had higher SCD1 levels in tumors than their paired non-tumor tissues, while the SCD1^low patients had lower tumoral SCD1 levels than non-tumor tissues. h Survival analysis of p53^mut and p53^wt group in sorafenib-treated cohort C⁴⁶ (n = 80 patients). i Representative IHC staining of URI, p53 and SCD1 in patients with p53^WT status from cohort C. Scale bar, 200 μm. j Spearman’s correlation between SCD1 H-score and p53 H-score in p53-wild type (p53-WT) tumors from cohort C (determined by two-tailed test) (n = 46 patients). k Spearman’s correlation between SCD1 H-score and URI H-score in p53-WT tumors from cohort C (determined by two-tailed test) (n = 46 patients). l Survival analysis of SCD1^high and SCD1^low patients in p53-WT tumors from cohort C (n = 46 patients). m, Survival analysis of URI^high and URI^low patients in p53-WT tumors from cohort C (n = 46 patients). n Survival analysis of p53^high and p53^low patients in p53-WT tumors from cohort C (n = 46 patients). o Survival analysis of URI^high/SCD1^high and other groups in p53-WT tumors from cohort C (n = 46 patients). Data are means ± SEM. HR: hazard ratio; Two-sided log-rank test (d, f–h, l–o), or two-tailed Mann–Whitney test (e). Source data are provided as a Source Data file.